Tag:
head and neck cancer
Latest Headlines
Latest Headlines
Idera's troubled TLR program founders in PhII cancer study
This morning the biotech highlighted just how problematic the field is when it announced that the lead drug in that pact--IMO-2055--failed a mid-stage study in advanced head and neck cancer.
Carbon nanoparticles charge up old cancer treatment to powerful effect
Carbon nanoparticles are galloping to the rescue once again. Scientists are exploring their use as a booster ingredient to enhance the effectiveness of an existing treatment for head-and-neck cancer....
Researchers fingerprint head, neck cancer for better diagnostics
Aggressive cancer treatment can be associated with a lot of side effects, but is often essential if the cancer is going to be life-threatening. Knowing how fast a cancer will progress is therefore
Gene may hold back skin, head, neck cancers
For scientists seeking to stop skin, head or neck cancers from developing, a single gene exists that could be the ultimate weapon for the job, according to an international team of researchers from
Merck KGaA nixes development of Idera Pharma cancer drug
Idera Pharmaceuticals' advancement of a Toll-like receptor agonist against cancer has taken a blow. Partner Merck KGaA has informed the developer ( $IDRA ) that the German pharma is ending development
Introgen gets positive Phase III Advexin data
Introgen Therapeutics announced that a preliminary analysis of a late-stage trial of Advexin confirmed their mid-stage efficacy data for patients with recurrent head and neck cancer. And researchers
ALSO NOTED: Meda buys late-stage drugs;Debiopharm licenses peptide;and much more...
> How might drugmakers navigate the rocky waters of generic competition, cautious regulators, safety scandals, globalization, and so on? Seek help with the itinerary from an expert, perhaps. At
Genzyme to collaborate on gene therapy in China
Readers of FierceBiotech are no strangers to all types of licensing deals, but Genzyme's new collaboration with a Chinese company may stand out. Genzyme is partnering with Shanghai-based Sunway
Introgen reports biomarker link to new therapy
Introgen Therapeutics says that their researchers have found a statistically significant link between an abnormal p53 biomarker and response to their experimental therapy for head and neck cancer.
ALSO NOTED: Vernalis reports "striking" weight loss in trial; Genmab shares surge on Phase III; FDA wants more time on Entereg;
>Â Vernalis is reporting "striking" weight loss results in its Phase I trial of the obesity drug V24343.
